Respiratory syncytial (RS) virus is the main cause of severe respiratory infections in newborns and infants during the first year of life. In the recent years, search is under way for chemo- and immune replacement therapy preparations for etiotropic RS-infection therapy. Procedures have been developed to prepare immunoglobulins and Chigain preparations having a target-oriented action. They were clinically tested. There was a positive dynamics in the clinical manifestations of the disease and a positive influence on immunological parameters in children.